Future directions in hemostasis: Normalizing the lives of patients with hemophilia

Thrombosis Research

Volumn 125, Issue SUPPL. 1, 2010, Pages

  Carr Jr , Marcus E ^a,b,c  

^a NOVO NORDISK INC   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug delivery systems; Engineered altered activity clotting factors; Prolonged half life proteins; Recombinant clotting factors; Targeting of activated platelets

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR; GLUTAMIC ACID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

BIOENGINEERING; BLEEDING; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; GENE THERAPY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; ROOM TEMPERATURE; THROMBIN TIME;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; HEMATOLOGY; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HEMOSTATICS; HUMANS; TREATMENT OUTCOME;

EID: 77949267125     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.01.044     Document Type: Review

References (38)

1. Mannucci P.M., and Tuddenham E.G. The hemophilias-from royal genes to gene therapy. N Engl J Med 344 (2001) 1773-1779
2. Viiala N.O., Larsen S.R., and Rasko J.E. Gene therapy for hemophilia: clinical trials and technical tribulations. Semin Thromb Hemost 35 (2009) 81-92
3. Coppola A., Franchini M., and Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost 101 (2009) 674-681
4. Jimenez-Yuste V., Rodriguez-Merchan E.C., Alvarez M.T., Quintana M., Martin-Salces M., and Hernandez-Navarro F. Experiences in the prevention of arthropathy in haemophila patients with inhibitors. Haemophilia 14 Suppl 6 (2008) 28-35
5. Pierce G. Fusion protein technology-potential treatment for hemophilia. Presentation at WFH Global Forum. September 2009. Montreal, Canada. www wfh org 2009.
6. Saenko E.L., and Pipe S.W. Strategies towards a longer acting factor VIII. Haemophilia 12 Suppl 3 (2006) 42-51
7. Hamidi M., Azadi A., and Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv 13 (2006) 399-409
8. DeFrees S., Wang Z.G., Xing R., Scott A.E., Wang J., Zopf D., et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16 (2006) 833-843
9. Metzner H.J., Weimer T., Kronthaler U., Lang W., and Schulte S. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX. Thromb Haemost 102 (2009) 634-644
10. Dumont J.A., Low S.C., Peters R.T., and Bitonti A.J. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20 (2006) 151-160
11. Powell J.S., Nugent D.J., Harrison J.A., Soni A., Luk A., Stass H., et al. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A. J Thromb Haemost 6 (2008) 277-283
12. Spira J., Plyushch O.P., Andreeva T.A., and Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 108 (2006) 3668-3673
13. Gregoriadis G., Fernandes A., Mital M., and McCormack B. Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics. Cell Mol Life Sci 57 (2000) 1964-1969
14. McCarthy K., Stewart P., Sigman J., Read M., Keith Jr. J.C., Brinkhous K.M., et al. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost 87 (2002) 824-830
15. Russell K.E., Olsen E.H., Raymer R.A., Merricks E.P., Bellinger D.A., Read M.S., et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood 102 (2003) 4393-4398
16. Haya S., Moret A., Cid A.R., Cortina V., Casana P., Cabrera N., et al. Inhibitors in haemophilia A: current management and open issues. Haemophilia 13 Suppl 5 (2007) 52-60
17. Hilgartner M., Aledort L., Andes A., and Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 30 (1990) 626-630
18. Leissinger C.A., Becton D.L., Ewing N.P., and Valentino L.A. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia 13 (2007) 249-255
19. Negrier C., Goudemand J., Sultan Y., Bertrand M., Rothschild C., and Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 77 (1997) 1113-1119
20. Siegmund B., Richter H., and Pollmann H. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?. Haemophilia 11 (2005) 638-641
21. Hoots W.K., Ebbesen L.S., Konkle B.A., Auerswald G.K., Roberts H.R., Weatherall J., et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 14 (2008) 466-475
22. Jimenez-Yuste V., Quintana M., Alvarez M.T., Martin-Salces M., and Hernandez-Navarro F. "Primary prophylaxis" with rFVIIa in a patient with severe haemophilia A and inhibitor. Blood Coagul Fibrinolysis 19 (2008) 719-720
23. Konkle B.A., Ebbesen L.S., Erhardtsen E., Bianco R.P., Lissitchkov T., Rusen L., et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5 (2007) 1904-1913
24. Morfini M., Auerswald G., Kobelt R.A., Rivolta G.F., Rodriguez-Martorell J., Scaraggi F.A., et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 13 (2007) 502-507
25. Saxon B.R., Shanks D., Jory C.B., and Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 86 (2001) 1126-1127
26. Young G., McDaniel M., and Nugent D.J. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 11 (2005) 203-207
27. DiMichele D., and Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 12 (2006) 352-362
28. Glazer S., Hedner U., and Falch J.F. Clinical update on the use of recombinant factor VII. Adv Exp Med Biol 386 (1995) 163-174
29. Key N.S., Aledort L.M., Beardsley D., Cooper H.A., Davignon G., Ewenstein B.M., et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 80 (1998) 912-918
30. Lusher J., Ingerslev J., Roberts H., and Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 9 (1998) 119-128
31. Gopalakrishnan R, Hedner U, Ghosh S, Nayak R, Allen TC, Pendurthi UR, Rao LV. Bio-distribution of pharmacologically administered rFVIIa. J Thromb Haemost 2010;8:301-10.
32. Bysted B.V., Scharling B., Moller T., and Hansen B.L. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Haemophilia 13 (2007) 527-532
33. Sorensen B., Persson E., and Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 137 (2007) 158-165
34. Liu T., Zhang X., Pan J., Sim D., McLean K., Cui Z., et al. Enhanced and prolonged efficacy of a novel recombinant FVIIa variant (BAY86-6150) for acute and prophylactic treatments in hemophilia A (HemA) mice. J Thromb Haemost 7 Suppl 2 (2009) Abstract OC-WE-057
35. Pan J., Kim J., Zhu D., Blank E., Zhang X., Liu T., et al. Binding to activated platelets and enhanced clotting properties of the recombinant FVIIa analogue Bay7. J Thromb Haemost 7 Suppl 2 (2009) Abstract OC-WE-059
36. Persson E., Kjalke M., and Olsen O.H. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci U S A 98 (2001) 13583-13588
37. Saenko E.L., Ananyeva N.M., Shima M., Hauser C.A., and Pipe S.W. The future of recombinant coagulation factors. J Thromb Haemost 1 (2003) 922-930
38. Prasad S., Lillicrap D., Labelle A., Knappe S., Keller T., Burnett E., et al. Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A. Blood 111 (2008) 672-679